DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, will present new in vivo data demonstrating its selective BRD4 (BD2) inhibitor DC-9476 is ...
In a Enzalutamide resistant prostate cancer cell line, treatment with AUTX-703 alone or in combination with Enzalutamide for up to 14 days reduced cell growth, Myc and androgen receptor (AR) signaling ...